This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

5 Rocket Stocks Geared to Rally This Week

Stocks in this article: SUVARCHDARMHCRM

Church & Dwight

In a world where conventional consumer product stocks are the biggest blue chips on the NYSE, it's no huge surprise that mid-cap name Church & Dwight (CHD) doesn't have the same name recognition among investors that Procter & Gamble (PG) or Clorox (CLX) get. But while C&D's market cap isn't blue chip, its brands are: Arm & Hammer, Oxiclean, Nair and Orajel are some of the best-known names in CHD's portfolio.

Innovation has been big for Church & Dwight. By leveraging legacy names like Arm & Hammer in new products, the firm has managed to fuel growth in one of the oldest consumer brands in the country. Arm & Hammer's ownership of a boring, low-moat business like baking soda is attractive too -- it provides hefty margins and opened the door for the double-digit annualized growth that CHD has turned out in the shadow of the Great Recession.

Church & Dwight is in solid financial shape, with net margins in the double digits and a debt load that's more than manageable. While the firm's dividend payout falls short of the sort of income that gets shelled out at bigger consumer product firms, a handful of high-growth brands more than makes up for it.

Varian Medical Systems

Palo Alto-based radiation technology firm Varian Medical Systems (VAR) makes devices used for cancer treatment, x-rays, and even nonmedical applications like security products. The firm is the league leader in the oncology market, having established one of the first commercial radiation therapy systems to hit the market. Radiation systems are complex, and as a result making them is capital intense and fraught with challenges -- that gives Varian a measurable advantage over competitors.

New advances in Varian's systems provide higher levels of precision in irradiating cancerous cells, a big advantage considering the side effects of radiation on healthy cells. That fact, coupled with Varian's name, should help spur sales of new therapy equipment as medical facilities upgrade or grow their treatment capabilities. An aging population is another big factor for Varian in the coming years -- as the pool of patients in need of Varian's offerings increases, so too should the firm's sales.

Varian's expertise in high-precision medical applications makes less exacting devices a no-brainer for the company. Newer markets like x-rays and security take the firm's existing IP and manufacturing expertise and simply apply it to a new use -- that dramatically reduces the development costs that Varian shells out to bring products to market relative to peers. As emerging market healthcare systems modernize their disease-fighting arsenals, Varian should see a big opportunity in boosting its international presence as well.

To see all of this week's Rocket Stocks in action, check out the Rocket Stocks portfolio at Stockpickr.

RELATED LINKS:



Follow Stockpickr on Twitter and become a fan on Facebook.

At the time of publication, author had no positions in stocks mentioned.

Jonas Elmerraji, CMT, is a senior market analyst at Agora Financial in Baltimore and a contributor to TheStreet. Before that, he managed a portfolio of stocks for an investment advisory returned 15% in 2008. He has been featured in Forbes , Investor's Business Daily, and on CNBC.com. Jonas holds a degree in financial economics from UMBC and the Chartered Market Technician designation.

4 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,828.24 +0.49 0.00%
S&P 500 2,065.68 -7.15 -0.34%
NASDAQ 4,790.4040 +3.0870 0.06%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs